Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634552 · ClinicalTrials.gov registry record · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2 study of Hematological Malignancies, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 510
- Enrollment target
- 20
- Study locations
NCT04634552: Recruiting Phase 2 study of Hematological Malignancies, sponsored by Janssen Research & Development.
NCT04634552 is a Phase 2 study of Hematological Malignancies that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 510 participants, below the 745-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04634552, a Phase 2 study of Hematological Malignancies, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 510 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Primary Outcome
ORR is defined as the proportion of participants who have a partial response (PR) or better according to the international myeloma working group (IMWG) criteria.
Conditions Studied
Interventions
- DRUG Talquetamab
Study Locations (20)
Other
- UZ Antwerpen - Edegem
- UZ Leuven - Leuven
- CHU de Liège - Domaine Universitaire du Sart Tilman - Liège
- UCL - Saint Luc - Woluwe-Saint-Lambert
- Peking University Third Hospital - Beijing
- Sun Yat Sen University Cancer Center - Guangzhou
New York
- NYU Langone Health - New York
- Mount Sinai Medical Center - New York
- University of Rochester Medical Center - Rochester
Alabama
- University of Alabama Birmingham - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- City of Hope - Duarte
Florida
- Memorial Healthcare System - Hollywood
Georgia
- Emory University Winship Cancer Institute - Atlanta
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 2 |
What NCT04634552 shows while recruiting
NCT04634552 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, below the 745-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Talquetamab is the first listed.
NCT04634552 names 20 study sites across 13 states, led by Other, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT04634552 about?
NCT04634552 is a clinical study titled "A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
What is the current status of trial NCT04634552?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2021-02-01. Estimated completion is 2029-03-30.
What conditions does trial NCT04634552 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT04634552?
The interventions under investigation include: Talquetamab (DRUG).
Who is sponsoring clinical trial NCT04634552?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04634552 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04634552's enrollment target sits among peer trials
510 2nd of 16 the highest of 16 other Hematological Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematological Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
COMPLETED · Phase 2
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RECRUITING
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
- NCT05561387 · 510 participants · Phase 3
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI